中国民康医学
中國民康醫學
중국민강의학
MEDICAL JOURNAL OF CHINSEE PEOPLE HEALTH
2014年
13期
27-29,32
,共4页
魏英%杨忠%尹建兵%潘惠%胡建伟
魏英%楊忠%尹建兵%潘惠%鬍建偉
위영%양충%윤건병%반혜%호건위
度洛西汀%艾司西酞普兰%抑郁症%躯体化症状
度洛西汀%艾司西酞普蘭%抑鬱癥%軀體化癥狀
도락서정%애사서태보란%억욱증%구체화증상
Duloxetine%Escitalopram%Depression%Somatization symptom
目的:比较度洛西汀与艾司西酞普兰对急性期伴躯体化症状抑郁症的疗效及安全性。方法:70例门诊和住院患者,随机分为度洛西汀治疗35例为研究组,艾司西酞普兰治疗35例为对照组,疗程8周。采用17项汉密尔顿抑郁量表( HAMD17)和汉密尔顿焦虑量表(HAMA)评价症状严重程度,药物不良反应评价用TESS。结果:两组患者治疗后HAMD和HAMA评分较治疗前均有显著性降低(P<0.01);第8周研究组患者与对照组有效率分别为78.79%、53.13%,两组患者疗效差异有统计学意义(P<0.05)。两组患者与药物有关的不良反应出现频率的差异无统计学意义(P>0.05)。结论:与艾司西酞普兰比较,度洛西汀治疗伴躯体化症状的抑郁症疗效更为确切,起效较快,安全性较高。
目的:比較度洛西汀與艾司西酞普蘭對急性期伴軀體化癥狀抑鬱癥的療效及安全性。方法:70例門診和住院患者,隨機分為度洛西汀治療35例為研究組,艾司西酞普蘭治療35例為對照組,療程8週。採用17項漢密爾頓抑鬱量錶( HAMD17)和漢密爾頓焦慮量錶(HAMA)評價癥狀嚴重程度,藥物不良反應評價用TESS。結果:兩組患者治療後HAMD和HAMA評分較治療前均有顯著性降低(P<0.01);第8週研究組患者與對照組有效率分彆為78.79%、53.13%,兩組患者療效差異有統計學意義(P<0.05)。兩組患者與藥物有關的不良反應齣現頻率的差異無統計學意義(P>0.05)。結論:與艾司西酞普蘭比較,度洛西汀治療伴軀體化癥狀的抑鬱癥療效更為確切,起效較快,安全性較高。
목적:비교도락서정여애사서태보란대급성기반구체화증상억욱증적료효급안전성。방법:70례문진화주원환자,수궤분위도락서정치료35례위연구조,애사서태보란치료35례위대조조,료정8주。채용17항한밀이돈억욱량표( HAMD17)화한밀이돈초필량표(HAMA)평개증상엄중정도,약물불량반응평개용TESS。결과:량조환자치료후HAMD화HAMA평분교치료전균유현저성강저(P<0.01);제8주연구조환자여대조조유효솔분별위78.79%、53.13%,량조환자료효차이유통계학의의(P<0.05)。량조환자여약물유관적불량반응출현빈솔적차이무통계학의의(P>0.05)。결론:여애사서태보란비교,도락서정치료반구체화증상적억욱증료효경위학절,기효교쾌,안전성교고。
Objective:To compare effectiveness and safety of duloxetine and escitalopram in treatment of depression withsoma-tization symptoms. Methods:A total of 70 outpatients and inpatients with depression were randomly divided into duloxetine ( 35 pa-tients)group and escitalopram(35 patients)group. The duration of treatment was 8 weeks. Severity was assessed by 17-item Hamilton depression scale (HAMD)17 and Hamilton anxiety scale(HAMA). The safety was evaluated with treatment emergent symptom scale ( TESS) . Results:The HAMD and HAMA scores after the treatment of the two groups were significantly lower than those before the treatment (P<0. 01). At the 8th weeks, the effective rates of research group and control group were 78. 79% and 53. 13%, and the difference was statistically significant (P<0. 05). Therewere no significant statistical differences in the adverse event frequencies be-tween the two groups (P>0. 05). Conclusions:Duloxetine would have better efficacy and higher safety, and takes effects more rapidly in the treatment of depression with somatization symptoms, compared with escitalopram.